Cover Image
市場調查報告書

ReGenX Biosciences, LLC:產品平台分析

ReGenX Biosciences, LLC - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 253733
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
ReGenX Biosciences, LLC:產品平台分析 ReGenX Biosciences, LLC - Product Pipeline Review - 2014
出版日期: 2014年12月10日 內容資訊: 英文 35 Pages
簡介

ReGenX Biosciences, LLC 是開發並提供各種疾病治療藥的生物製藥公司。特別是提供代謝,肌肉,血液,眼睛性,神經退化性疾病相關的治療藥。此外還有基因治療,遺傳基因調節,蛋白質治療藥,遺傳基因疫苗,同時也致力於蛋白質篩檢的領域的產品開發,提供試劑服務。

ReGenX Biosciences, LLC的基本資料

  • ReGenX Biosciences, LLC概要
  • 主要資訊
  • 企業資料

ReGenX Biosciences, LLC:R&D概要

  • 主要的治療範圍

ReGenX Biosciences, LLC:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

ReGenX Biosciences, LLC:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

ReGenX Biosciences, LLC:藥物簡介

  • Gene Therapy to Activate Arylsulfatase A for Metachromatic Leukodystrophy
  • Gene Therapy to Activate Factor IX for Hemophilia B
  • Gene Therapy to Activate Tripeptidyl Peptidase 1 for Batten Disease
  • AP-22594
  • Gene Therapy for Alzheimer's Disease
  • Gene Therapy for Wet Age-Related Macular Degeneration
  • Gene Therapy to Activate Arylsulfatase B for Maroteaux-Lamy Syndrome
  • Gene Therapy to Activate Iduronidase for Hurler Syndrome
  • Gene Therapy to Activate LDL Receptor for Homozygous Familial Hypercholesterolemia
  • Gene Therapy to Activate RPE65 for Leber Congenital Amaurosis (LCA)
  • Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa

ReGenX Biosciences, LLC:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

ReGenX Biosciences, LLC:最近的開發平台趨勢

ReGenX Biosciences, LLC:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06644CDB

Summary

Global Markets Direct's, 'ReGenX Biosciences, LLC - Product Pipeline Review - 2014', provides an overview of the ReGenX Biosciences, LLC's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ReGenX Biosciences, LLC's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of ReGenX Biosciences, LLC including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of ReGenX Biosciences, LLC's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the ReGenX Biosciences, LLC's pipeline products

Reasons to buy

  • Evaluate ReGenX Biosciences, LLC's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of ReGenX Biosciences, LLC in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the ReGenX Biosciences, LLC's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of ReGenX Biosciences, LLC and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of ReGenX Biosciences, LLC
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of ReGenX Biosciences, LLC and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ReGenX Biosciences, LLC Snapshot
    • ReGenX Biosciences, LLC Overview
    • Key Information
    • Key Facts
  • ReGenX Biosciences, LLC - Research and Development Overview
    • Key Therapeutic Areas
  • ReGenX Biosciences, LLC - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • ReGenX Biosciences, LLC - Pipeline Products Glance
    • ReGenX Biosciences, LLC - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • ReGenX Biosciences, LLC - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • ReGenX Biosciences, LLC - Drug Profiles
    • Gene Therapy to Activate Arylsulfatase A for Metachromatic Leukodystrophy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate Factor IX for Hemophilia B
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate Tripeptidyl Peptidase 1 for Batten Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AP-22594
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Alzheimer's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Wet Age-Related Macular Degeneration
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate Arylsulfatase B for Maroteaux-Lamy Syndrome
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate Iduronidase for Hurler Syndrome
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate LDL Receptor for Homozygous Familial Hypercholesterolemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate RPE65 for Leber Congenital Amaurosis (LCA)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • ReGenX Biosciences, LLC - Pipeline Analysis
    • ReGenX Biosciences, LLC - Pipeline Products by Target
    • ReGenX Biosciences, LLC - Pipeline Products by Route of Administration
    • ReGenX Biosciences, LLC - Pipeline Products by Molecule Type
    • ReGenX Biosciences, LLC - Pipeline Products by Mechanism of Action
  • ReGenX Biosciences, LLC - Recent Pipeline Updates
  • ReGenX Biosciences, LLC - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ReGenX Biosciences, LLC, Key Information
  • ReGenX Biosciences, LLC, Key Facts
  • ReGenX Biosciences, LLC - Pipeline by Indication, 2014
  • ReGenX Biosciences, LLC - Pipeline by Stage of Development, 2014
  • ReGenX Biosciences, LLC - Monotherapy Products in Pipeline, 2014
  • ReGenX Biosciences, LLC - Partnered Products in Pipeline, 2014
  • ReGenX Biosciences, LLC - Partnered Products/ Combination Treatment Modalities, 2014
  • ReGenX Biosciences, LLC - Out-Licensed Products in Pipeline, 2014
  • ReGenX Biosciences, LLC - Out-Licensed Products/ Combination Treatment Modalities, 2014
  • ReGenX Biosciences, LLC - Phase I, 2014
  • ReGenX Biosciences, LLC - Preclinical, 2014
  • ReGenX Biosciences, LLC - Pipeline by Target, 2014
  • ReGenX Biosciences, LLC - Pipeline by Route of Administration, 2014
  • ReGenX Biosciences, LLC - Pipeline by Molecule Type, 2014
  • ReGenX Biosciences, LLC - Pipeline Products by Mechanism of Action, 2014
  • ReGenX Biosciences, LLC - Recent Pipeline Updates, 2014

List of Figures

  • ReGenX Biosciences, LLC - Pipeline by Top 10 Indication, 2014
  • ReGenX Biosciences, LLC - Pipeline by Stage of Development, 2014
  • ReGenX Biosciences, LLC - Monotherapy Products in Pipeline, 2014
  • ReGenX Biosciences, LLC - Out-Licensed Products in Pipeline, 2014
  • ReGenX Biosciences, LLC - Pipeline by Top 10 Target, 2014
  • ReGenX Biosciences, LLC - Pipeline by Top 10 Route of Administration, 2014
  • ReGenX Biosciences, LLC - Pipeline by Top 10 Molecule Type, 2014
  • ReGenX Biosciences, LLC - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top